Substituted aromatic compounds and pharmaceutical uses thereof
The present invention relates to substituted aromatic compounds of Formula I and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds in the prevention and/or treatment of various diseases and conditions in subjects, including the prevention or treatment of (i) blood disorders, (ii) renal disorders, a nephropathies, or renal disorder complications; (iii) inflammatory-related diseases; and/or (iv) oxidative stress related disorders.
1. A method for treating anemia and/or leukopenia by stimulating production and/or inhibiting the decrease of normal leukocytes and/or normal erythrocytes in a patient in need thereof, comprising administering to the patient a pharmacologically effective amount of a compound represented by Formula II:
or a pharmaceutically acceptable salt thereof,
wherein:
n is 1;
Q is C 1 -C 2 alkyl optionally substituted with one R a substituent;
R 1 is straight chain C 5 alkyl, C 6 alkyl, C 5 -C 6 alkenyl, or C 5 -C 6 alkynyl;
R 2 is H, halogen, haloalkyl, OR b , SR b , or NR c R d ;
R 3 is H, halogen, haloalkyl, straight chain C 1 -C 4 alkyl, OR b , SR b , or NR c R d ;
R 4 is H, halogen, haloalkyl, C 1 -C 4 alkyl, OR b , SR b , or NR c R d ;
R 5 is H or OR b ;
R a is OR b , SR b , or NR c R d ;
R b is H; and
R c and R d are independently chosen from: H and C 1 -C 4 alkyl.
2. The method of claim 1 , wherein R 1 is straight chain C 5 alkyl, C 6 alkyl, or C 5 -C 6 alkenyl; and R 2 is H, halogen, haloalkyl, or OR b .
3. The method of claim 1 , wherein R 3 is independently chosen from: H, halogen, haloalkyl, straight chain C 1 -C 4 alkyl, and OR 6 ; and R 4 is independently chosen from: H, halogen, haloalkyl, C 1 -C 4 alkyl, and OR b .
4. The method of claim 1 , wherein R a is OR b .
5. The method of claim 1 , wherein the pharmaceutically acceptable salt is a base addition salt, and the base addition salt is a metal counterion, the metal counterion is sodium, magnesium, calcium, potassium or lithium.
6. The method of claim 5 , wherein the metal counterion is sodium.
7. The method of claim 1 , wherein the compound is selected from the group consisting of:
and other pharmaceutically acceptable salts thereof and the acid form thereof.
8. The method of claim 7 , wherein the compound is:
9. The method of claim 1 , wherein the method is for treating anemia.
10. The method of claim 9 , wherein the administration of said compound stimulates erythropoiesis in the patient.
11. A method for treating a blood disorder selected from anemia, and leukopenia in a patient in need thereof, comprising administering to the patient a pharmacologically effective amount of a compound selected from
and other pharmaceutically acceptable salts thereof and the acid form thereof.
12. The method of claim 11 , wherein the pharmaceutically acceptable salt is a base addition salt.
13. The method of claim 12 , wherein the base addition salt is a metal counterion.
14. The method of claim 13 , wherein the metal counterion is sodium, magnesium, calcium, potassium or lithium.
15. The method of claim 14 , wherein the metal counterion is sodium.
16. The method of claim 11 , wherein the administration of said compound stimulates hematopoiesis and/or erythropoiesis in the patient.
17. The method of claim 1 , wherein the method is for treating leukopenia.
18. The method of claim 17 , wherein the leukopenia is neutropenia.
19. The method of claim 17 , wherein the administration of said compound stimulates hematopoiesis in the patient.
20. The method of claim 1 , wherein the anemia and/or leukopenia is caused by chemotherapy.